Moleculin Biotech, Inc. (MBRX) Dividend History

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology drugs and treatments for difficult-to-treat cancers. The company specializes in the research and development of small molecule therapeutics targeting cancer metabolism, tumor microenvironment, and resistant cancer cells. Moleculin's pipeline includes compounds designed for oral administration, aiming to address unmet medical needs in oncology.

5300 Memorial Drive, Houston, TX, 77007
Phone: 713-300-5160
Website: https://www.moleculin.com

Dividend History

Moleculin Biotech, Inc. currently does not pay dividends

Company News

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin reported positive results from a Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases. The trial showed improved overall survival and progression-free survival, with a clinical benefit rate of 59.4%.

GlobeNewswire Inc.
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.

Benzinga
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?

Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.

Zacks Investment Research

Featured Companies: ARDX ESPR LNTH

Page data last updated 07/25/2025 01:37:12 UTC